Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | MGLL | Q99685 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LPAR2 | Q9HBW0 | 3/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.33 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.33 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30372269 | 0.91 | MEN1 (0.52) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL1469721 | 0.91 | MEN1 (0.52) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL29518865 | 0.91 | MEN1 (0.52) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL14266910 | 0.89 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL823738 | 0.89 | MEN1 (0.48) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL823872 | 0.84 | LMNA (0.33) | MAPTEPHX2CYP2C19LPAR2LPAR3 | |
| SCHEMBL19028022 | 0.82 | ALDH1A1 (0.49) | TSHR | |
| SCHEMBL30917919 | 0.82 | CES2 (0.42) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL29518923 | 0.77 | ALDH1A1 (0.38) | MEN1THRBHTTKMT2AMAPT | |
| SCHEMBL1471178 | 0.77 | ALDH1A1 (0.38) | MEN1THRBHTTKMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8142720-B2 | Molecules suitable for binding to a metal layer for covalently immobilizing biomolecules | IMEC (BE) | 2012-03-27 | — | — | US | disclosed |
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | IMEC (BE) | 2010-11-11 | — | — | US | disclosed |
| US-7770437-B2 | Thiol or disulfide molecules having poly(ethylene oxide) groups for use in a self assembled monolayer bound to a metal layer for covalently immobilizing biomolecules in a biosensor | IMEC (BE) | 2010-08-10 | — | — | US | disclosed |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | IMEC (BE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100284860-A1 | MOLECULES SUITABLE FOR BINDING TO A METAL LAYER FOR COVALENTLY IMMOBILIZING BIOMOLECULES | EBPL, SPR, MB | MEN1 4679/4885THRB 1888/4885HTT 4857/4885 |
| US-20070272003-A1 | 2-(2-{2-[2-(2-{2-[2-(11-mercaptoyldisulfanyl-undecyloxy)ethoxy]ethoxy}ethoxy)ethoxy]ethoxy} acetic acid pentafluorophenyl ester; poly(ethylene oxide) groups resist nonspecific adsorption and enhance the specific affinity interactions | EBPL, AEBP2, NAPA | MEN1 4859/4885THRB 1883/4885HTT 4798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.